Last updated: 2026-09-05 22:36:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
60 Degrees Pharmaceuticals, Inc. (SXTP) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $0.95, with a market capitalization of $3.34M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0.90 to $8.62. This page covers its latest market performance, valuation, price trends and company information.
$3.34M | |
$0.93 | |
$2,076.00 | |
$0.90 | |
$0.93 | |
54.30K | |
-- | |
-- | |
$8.62 | |
$0.90 | |
-- | |
-- |
60 Degrees Pharmaceuticals, Inc. (SXTP) last closed at $0.93 as of 2026-09-04 23:31:00, unchanged from the previous close of $0.93.
During the latest regular trading session, SXTP traded between $0.90 and $2,076.00, with a volume of 54.30K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, 60 Degrees Pharmaceuticals, Inc. (SXTP) moved from $1.03 to $0.95, representing a decline of 7.77% ($0.08).
The stock traded between $0.90 and $0.99 during the period. The latest price is near the middle of the 7-day range, indicating strong downward.
The average daily volume was 53.56 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 0.6%
SXTP is currently trading at $0.95, placing it 0.6% of the way from its 52-week low of $0.90 to its 52-week high of $8.62. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of 60 Degrees Pharmaceuticals, Inc. (SXTP) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.